Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
DURHAM, N.C., Jan. 05, 2017 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced that Jeff Wolf, Heat’s Chief Executive Officer, will present an overview of the company at the Biotech Showcase 2017 Conference on Wednesday, January 11, 2017, at 9:30 a.m. Pacific Standard Time in Room 3, at the Hilton San Francisco Union Square in San Francisco, California.
The link to the live audio webcast and replay of the presentation may be accessed on Heat’s corporate website at http://ir.heatbio.com/events-presentations. The webcast will be archived on the company’s website for a period of three months.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that are designed to activate a patient’s immune system against cancer utilizing an engineered form of gp96, a protein that activates the immune system when cells die. Heat’s highly specific T cell-stimulating therapeutic vaccine platform technologies, ImPACT and ComPACT, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 1b trial with HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC) and a Phase 2 trial with HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC).
Heat’s wholly-owned subsidiary, Zolovax, Inc., is developing therapeutic and preventative vaccines to treat infectious diseases based on Heat’s gp96 vaccine technology, with a current focus on the development of a Zika vaccine in conjunction with the University of Miami. The Zolovax patent portfolio also includes gp96 vaccines targeting West Nile virus, Dengue and yellow fever among others.
For more information, please visit www.heatbio.com.
Contact: Jennifer Almond Investor and Media Relations 919-240-7133 [email protected]
